Get €500 (or $500) on your prepaid balance! Use it for premium subscriptions or job postings. Read more Close

Affymetrix announces winners of the 2016 EMEA Tumor Profiling Grant Award

Announcement Created on 26 Apr 2016 by Aleksander Benjak

Attention!

This article was published before automated invoicing was introduced in 2016. Some functions may not work as intended. Please contact us if you need more information.

Tumor grant profiling banner_Life Science Network_winners announced-edit.jpg

Affymetrix has announced the three winners of the 2016 EMEA Affymetrix Tumor Profiling Grant Program.

The grant program, first launched in 2014, is designed to support translational cancer researchers in the discovery and validation of novel diagnostic, prognostic, and therapeutic biomarkers that may address an unmet clinical need. The qualifying grant projects must use a multi-omics, systems-based approach that analyzes data from multiple molecular and cellular levels to identify robust cancer biomarkers for future application in the clinic. The high level of interest from scientists reflects a growing appreciation of the value of multi-parametric profiling of tumor samples.

 

The winners of the 2016 Affymetrix Tumor Profiling Grant Program are:

Dr Joseph Carlson
Karolinska University Hospital, Department of Clinical Pathology
Integrative profiling of high-grade uterine sarcomas: Identification of intrinsic subtypes, classification and prognosis by RNA gene expression and copy number variation

Dr Rachel Crossland
Newcastle University, Northern Institute for Cancer Research
Targeting cancer pathways driving chemoresistance in aggressive B-cell lymphoma

Dr Marialuisa Sensi
Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Experimental Oncology and Molecular Medicine
Identification of molecular biomarkers of pathologic downstaging to pT0 in muscle-invasive urothelial carcinoma of the bladder

The winners are awarded with products from Affymetrix to investigate and combine analysis of at least two different analytes – DNA, RNA, or protein – across 30 tumor samples. The discovery and validation of biomarkers from these projects has the potential to inform better treatment strategies and prognosis prediction, improving overall patient outcome.

Affymetrix plan to announce the next Tumor Profiling Grant later this year.

For more information please contact:

Frank Smith
EMEA Marketing Manager – Oncology & Translational Research
Affymetrix UK Ltd
Thermo Fisher Scientific
Mercury Park | Wycombe Lane | Wooburn Green | HP10 0HH | United Kingdom
Tel: +44 (0)1628 552518
[email protected]

Stats

  • Recommendations +2 100% positive of 2 vote(s)
  • Views 1999
  • Comments 0

Recommended by

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Loading ad...